Company news

Vanda Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

January 22, 2024

Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration

January 18, 2024

Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry

January 16, 2024

Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs

January 11, 2024

Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis

December 6, 2023

Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

December 3, 2023

Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences

November 8, 2023

Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 7, 2023

Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023

October 31, 2023

Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation

October 19, 2023

Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit

October 4, 2023

Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results

July 26, 2023

Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023

July 19, 2023

Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference

June 4, 2023

Vanda Pharmaceuticals Announces Presentations at SLEEP 2023

May 31, 2023

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

May 31, 2023

Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness

May 24, 2023

Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal

May 9, 2023

Vanda Pharmaceuticals Announces Presentations at DDW 2023

May 3, 2023

Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results

May 2, 2023

Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information

May 1, 2023

Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023

April 26, 2023

Vanda Prevails in Jet Lag Litigation Against the FDA

March 27, 2023

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

March 16, 2023

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

February 7, 2023

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023

January 31, 2023

Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

December 18, 2022

Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch

December 15, 2022

Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation

December 12, 2022

Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety

December 1, 2022

Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences

November 7, 2022

Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 1, 2022

Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

October 25, 2022

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

October 20, 2022

Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics

September 28, 2022

Vanda Pharmaceuticals announces notice of opportunity for an FDA hearing on the sNDA for HETLIOZ® in jet lag disorder

September 6, 2022

Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 2, 2022

Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022

July 26, 2022

Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference

June 1, 2022

Vanda Pharmaceuticals Announces Presentations at SLEEP 2022

May 30, 2022

Vanda Pharmaceuticals Announces Presentations at DDW 2022

May 18, 2022

Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results

May 4, 2022

Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference

May 3, 2022

Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022

April 27, 2022

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

February 22, 2022

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

February 16, 2022

Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis

February 3, 2022

Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN

January 13, 2022

Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences

November 9, 2021

Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results

November 2, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.